Page 1

TW TWIST BIOSCIENCE Twist Bioscience Reports Second Quarter Fiscal 2021 Financial Results May 6 , 2021 -- Revenue Growth of 62 % over Fiscal 2020 Second Quarter -- -- Order Growth of 69 % Year over Year -- -- Gross Margin of 39 % for the Quarter -- SOUTH SAN FRANCISCO , Calif .-- ( BUSINESS WIRE ) -- May 6 , 2021-- Twist Bioscience Corporation ( NASDAQ : TWST ) , a company enabling customers to succeed through its offering of high - quality synthetic DNA using its silicon platform , today reported financial results and business highlights for the second quarter of fiscal 2021 ended March 31 , 2021 . " The second quarter of our fiscal year delivered growth across all four areas of our business , with increasing revenue and very strong orders building momentum for the second half of the year , " said Emily M. Leproust , Ph.D. , CEO and co - founder of Twist Bioscience . " We signed new biopharma partnerships with multiple associated programs , and we continue to drive increasing density for our data storage vertical . " For the second half of fiscal 2021 we expect continued growth of our NGS and synbio customer base as we build out the Factory of the Future in Oregon . We intend to advance all programs with our biopharma partners while simultaneously generating data to support out - licensing for our proprietary antibodies . In addition , for data storage , we will continue to pursue innovative engineering and collaborate across the DNA Data Storage Alliance to prepare the market for this novel storage medium . " FISCAL 2021 SECOND QUARTER FINANCIAL RESULTS • Orders : Total orders received for the second quarter of fiscal 2021 were $ 41.7 million , compared to $ 24.6 million for the same period of fiscal 2020 . • Revenue : Total revenues were $ 31.2 million for the second quarter of fiscal 2021 compared to $ 19.3 million for the same period of fiscal 2020 . • Cost of Revenues : Cost of revenues for the second quarter of fiscal 2021 was $ 19.0 million compared to $ 13.6 million for the same period of fiscal 2020 . • Research and Development Expenses : Research and development expenses for the second quarter of fiscal 2021 were $ 15.8 million compared to $ 10.6 million for the same period of fiscal 2020 . • Selling , General and Administrative Expenses : Selling , general and administrative expenses for the second quarter of fiscal 2021 were $ 34.4 million compared to $ 27.2 million for the same period of fiscal 2020 . • Net Loss : Net loss for the second quarter of fiscal 2021 was $ 37.9 million , or $ 0.78 per share , compared to $ 31.8 million , or $ 0.85 per share , for the second quarter of fiscal 2020 . • Cash Position : As of March 31 , 2021 , the company had $ 555.7 million in cash , cash equivalents and short - term investments . " We increased our margin to 39 % , reflecting the impact of scaling our revenue , leveraging our fixed costs and the benefit of higher NGS product mix , " commented Jim Thorburn , CFO of Twist . " Importantly , the solid results demonstrate excellent execution across all teams at Twist . " Fiscal Second Quarter 2021 and Recent Highlights • Shipped products to approximately 1,700 customers in the second quarter of fiscal 2021 versus approximately 1,400 in the same period of fiscal 2020 . • Exercised our right of first refusal which gives a cost - effective option to double manufacturing capacity at the " Factory of the Future " just outside of Portland , Oregon • Launched the Twist NGS Methylation Detection System , a robust , end - to - end sample preparation and target enrichment solution for identifying methylated regions in the human genome . DNA methylation plays a key role in many biological processes including cancer . • Received Emergency Use Authorization ( EUA ) from the U.S. Food and Drug Administration ( FDA ) , together with Biotia , for the SARS - CoV - 2 Next - Generation Sequencing ( NGS ) Assay . • Partnered with Watchmaker Genomics to enable innovative research across a wide range of high throughput sequencing applications including tumor profiling , inherited disease detection , liquid biopsy assays and minimal residual disease monitoring . • Added new synthetic RNA controls to develop , validate and verify tests for SARS - CoV - 2 . The new controls include the